Question re Ldn

A board to discuss Low Dose Naltrexone (LDN) as a treatment for Multiple Sclerosis

Question re Ldn

Postby starey33 » Mon Jan 21, 2008 7:31 am

I use to be on ldn for a short time and just got lazy and quit taking it. I am seriously thinking about restarting the ldn, but my ques is i have chrones diease to so if i do not absorb things like the average person what can i take to ensure that the ldn is getting into my system any advice is greatly appreciated

Brenda
User avatar
starey33
Newbie
 
Posts: 2
Joined: Sat Aug 25, 2007 3:00 pm

Advertisement

Re: Question re Ldn

Postby NHE » Tue Jan 22, 2008 7:02 am

Hi Brenda,
starey33 wrote:i have chrones diease to so if i do not absorb things like the average person what can i take to ensure that the ldn is getting into my system

That might be a good question for either your pharmacist or your doctor.

NHE
User avatar
NHE
Volunteer Moderator
 
Posts: 3247
Joined: Sat Nov 20, 2004 4:00 pm

Postby superman » Wed Feb 20, 2008 12:44 pm

Some research proved that ldn was efficiency to fight Crohns so it will have a double positive effect on your health, although i do not know how it should be taken for that disease.

Low-dose naltrexone therapy improves active Crohn's disease.
Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.

Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.

OBJECTIVES: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease. METHODS: Eligible subjects with histologically and endoscopically confirmed active Crohn's disease activity index (CDAI) score of 220-450 were enrolled in a study using 4.5 mg naltrexone/day. Infliximab was not allowed for a minimum of 8 wk prior to study initiation. Other therapy for Crohn's disease that was at a stable dose for 4 wk prior to enrollment was continued at the same doses. Patients completed the inflammatory bowel disease questionnaire (IBDQ) and the short-form (SF-36) quality of life surveys and CDAI scores were assessed pretreatment, every 4 wk on therapy and 4 wk after completion of the study drug. Drug was administered by mouth each evening for a 12-wk period. RESULTS: Seventeen patients with a mean CDAI score of 356 +/- 27 were enrolled. CDAI scores decreased significantly (P= 0.01) with LDN, and remained lower than baseline 4 wk after completing therapy. Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission (P < 0.001). Improvement was recorded in both quality of life surveys with LDN compared with baseline. No laboratory abnormalities were noted. The most common side effect was sleep disturbances, occurring in seven patients. CONCLUSIONS: LDN therapy appears effective and safe in subjects with active Crohn's disease. Further studies are needed to explore the use of this compound.

PMID: 17222320 [PubMed - indexed for MEDLINE]
User avatar
superman
Family Member
 
Posts: 58
Joined: Mon Jan 22, 2007 4:00 pm


Return to Low Dose Naltrexone

Who is online

Users browsing this forum: No registered users